EP1334356A2 - Procede pour creer des animaux clones par rearrangement chromosomique - Google Patents
Procede pour creer des animaux clones par rearrangement chromosomiqueInfo
- Publication number
- EP1334356A2 EP1334356A2 EP01981389A EP01981389A EP1334356A2 EP 1334356 A2 EP1334356 A2 EP 1334356A2 EP 01981389 A EP01981389 A EP 01981389A EP 01981389 A EP01981389 A EP 01981389A EP 1334356 A2 EP1334356 A2 EP 1334356A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- isogenic
- animal
- cell
- haploid
- chromosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 297
- 238000000034 method Methods 0.000 title claims abstract description 172
- 210000000349 chromosome Anatomy 0.000 title claims abstract description 63
- 238000012546 transfer Methods 0.000 claims abstract description 105
- 210000003765 sex chromosome Anatomy 0.000 claims abstract description 61
- 238000009395 breeding Methods 0.000 claims abstract description 41
- 230000001488 breeding effect Effects 0.000 claims abstract description 41
- 210000001766 X chromosome Anatomy 0.000 claims abstract description 32
- 210000002593 Y chromosome Anatomy 0.000 claims abstract description 21
- 230000014639 sexual reproduction Effects 0.000 claims abstract description 19
- 230000002759 chromosomal effect Effects 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 208000031404 Chromosome Aberrations Diseases 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 117
- 210000003783 haploid cell Anatomy 0.000 claims description 116
- 210000001082 somatic cell Anatomy 0.000 claims description 94
- 210000004940 nucleus Anatomy 0.000 claims description 43
- 210000000287 oocyte Anatomy 0.000 claims description 42
- 210000002459 blastocyst Anatomy 0.000 claims description 36
- 210000000582 semen Anatomy 0.000 claims description 32
- 210000001161 mammalian embryo Anatomy 0.000 claims description 29
- 230000031864 metaphase Effects 0.000 claims description 28
- 210000003754 fetus Anatomy 0.000 claims description 19
- 230000021121 meiosis Effects 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 210000001840 diploid cell Anatomy 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 12
- 230000000392 somatic effect Effects 0.000 claims description 12
- 210000002308 embryonic cell Anatomy 0.000 claims description 11
- 239000003550 marker Substances 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 210000004508 polar body Anatomy 0.000 claims description 9
- 230000001568 sexual effect Effects 0.000 claims description 9
- 230000009027 insemination Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 7
- 108010000912 Egg Proteins Proteins 0.000 claims description 7
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 7
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 claims description 7
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 claims description 7
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 210000004681 ovum Anatomy 0.000 claims description 7
- 238000002689 xenotransplantation Methods 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 6
- 230000022131 cell cycle Effects 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 claims description 5
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims description 5
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 5
- 102000001974 Hyaluronidases Human genes 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 5
- OPQGFIAVPSXOBO-UHFFFAOYSA-N bohemine Chemical compound N1=C(NCCCO)N=C2N(C(C)C)C=NC2=C1NCC1=CC=CC=C1 OPQGFIAVPSXOBO-UHFFFAOYSA-N 0.000 claims description 5
- 238000012239 gene modification Methods 0.000 claims description 5
- 230000005017 genetic modification Effects 0.000 claims description 5
- 235000013617 genetically modified food Nutrition 0.000 claims description 5
- 229960002773 hyaluronidase Drugs 0.000 claims description 5
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 5
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- -1 Ca2+ ions Chemical class 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 210000002230 centromere Anatomy 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 210000004602 germ cell Anatomy 0.000 claims description 3
- 239000010985 leather Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 230000000394 mitotic effect Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 230000000644 propagated effect Effects 0.000 claims description 3
- 230000005945 translocation Effects 0.000 claims description 3
- 210000002268 wool Anatomy 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 241001416152 Bos frontalis Species 0.000 claims description 2
- 241000700198 Cavia Species 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims description 2
- 230000018486 cell cycle phase Effects 0.000 claims description 2
- 230000035558 fertility Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000013011 mating Effects 0.000 claims 7
- 241000283705 Capra hircus Species 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 230000004077 genetic alteration Effects 0.000 claims 2
- 231100000118 genetic alteration Toxicity 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 241000270322 Lepidosauria Species 0.000 claims 1
- 241001482592 Oreamnos americanus Species 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 abstract description 8
- 210000002257 embryonic structure Anatomy 0.000 description 12
- 238000010367 cloning Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 210000003917 human chromosome Anatomy 0.000 description 7
- 239000010902 straw Substances 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 244000309464 bull Species 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000521088 Coua Species 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 210000000723 mammalian artificial chromosome Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000282452 Ailuropoda melanoleuca Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 101150104214 HGPRT gene Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000982634 Tragelaphus eurycerus Species 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/101—Bovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/30—Bird
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
Definitions
- This invention concerns methods of cloning animals that incorporate methods for manipulating or shuffling chromosomes.
- the methods find important use in the fields of agriculture, xenotransplantation, laboratory science and species conservation, where shuffling of chromosomes can be used to correct chromosomal abnormalities, and to create autosomally isogenic, sexually non-isogenic cloned animals.
- Microcell-mediated chromosome transfer has been used for many years in order to introduce a single chromosome into a target cell.
- Saxon et al demonstrated the complete suppression of tumorigenicity in HeLa cells by introducing a single human chromosome via microcell fusion.
- Saxon et al. 1986, "Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells," EMBO J. 5: 3461-66.
- This technology was used by others to create libraries of human chromosomes, by fusing single human chromosomes carrying the HGPRT gene with HGPRT-deficient mouse cells.
- MACs mammalian artificial chromosomes
- inner cell mass cells cells from the blastocyst which form both somatic and germ cells
- inner cell mass cells were found to support a low rate of development to the blastocyst stage with some offspring obtained.
- trophectodermal cells the cells from the blastocyst that form the placenta
- trophectodermal cells did not support the development of the nuclear fusion to the blastocyst stage.
- somatic cells to be used for nuclear transfer could be used to facilitate complex genetic manipulations of donor cells, and particularly the replacement of chromosomes in cloned animals.
- the present invention makes use of somatic cell donor cells for nuclear transfer to create complex chromosomal arrangements, and particularly chromosomal replacements, in cloned and transgenic animals.
- This technology may be used to produce cloned cells, embryos, blastocysts, fetuses and animals that are autosomally isogenic and sexually non-isogenic, in order to make a population more uniform or improve quality control in xenotransplantation.
- Such chromosome shuffling techniques can also be used to eliminate chromosomal abnormalities, such as inversions or translocations from the clone of an animal, produce a sexual mate for an extinct animal where the genome of only one animal is extant, or to produce the opposite sex of an existing animal or embryo where the genome of only one sex is available or desired.
- somatic cells from the desired animal are isolated, and one X chromosome is removed and replaced with a Y chromosome from another animal.
- both X chromosomes may be replaced with the sex chromosomes - one X and one Y - from another mammal.
- Multiple females may be cloned from the original somatic cells, and males would be produced from the autosomally isogenic sexually non- isogenic (AISN) cells.
- AISN autosomally isogenic sexually non- isogenic
- the cloned bulls could then be used to breed females by sexual reproduction rather than by cloning.
- semen from these males can be frozen for use in artificial insemination in order to produce more females having the desired trait.
- the male AISN animals may be genetically modified to produce only female animals using the technology described in Application Serial No. 60/184,830, now PCT/US01/05932, herein incorporated by reference in its entirety. This would allow the marketing of semen and the ready propagation of female animals having a desirable genetic make-up while simultaneously preventing customers from breeding their the AISN animals on their own without exchange of compensation for the technology.
- single sex technology can also be used to produce all male offspring, and female AISN animals could be marketed as a business strategy.
- the chromosome shuffling techniques of the present invention may also be combined with nuclear transfer techniques designed to create homozygous diploids of desirable haploid genomes, in order to achieve allelically isogenic breeding pairs of animals that differ only as to their sex chromosomes, i.e., each is a complete autosomal homozygous diploid.
- allelically isogenic animals results in isogenic male and female offspring without the need for years of inbreeding or successive cloning in order to generate animals. Further, such breeding avoids the potential genetic diversity associated with sexual reproduction between cloned breeding pairs where crossing over and chromosomal segregation can result in the appearance of undesirable recessive traits in the progeny.
- allelically isogenic breeding pairs will have significant utility in the agricultural field where it is often desirable to propagate animals with specific traits such as high milk output, milk with specific lipid or protein profiles, or animals which produce meat, leather, wool or fiber having a desired characteristic.
- breeding pairs would also find utility in laboratory settings as well as xenotransplantation studies, where lowering the statistical "noise" from genetic diversity, or eliminating the risk of introducing viral contaminants is desirable.
- Autosomally and allelically isogenic breeding pairs provide the ultimate business model, whereby purchasers and handlers can be assured that desirable animals may be easily maintained via sexual reproduction or artificial insemination without the need for nuclear transfer techniques.
- Methods of making autosomally isogenic, allelically isogenic diploid nuclear transfer units are also encompassed, as are methods of making cells, oocytes, balstocysts, inner cell masses, ES cells, embryos, and individual animals having the same characteristics.
- An object of the invention is also to provide business methods for using the breeding pairs to mass produce animals that have been genetically modified, bred or selected to provide an advantage in a desired market, as well as business methods to maintain control over the breeding of such animals by marketing animals and/or semen that can only be used by purchasers and handlers to produce animals of a single sex.
- FIG. 1 In protocol for Percoll separation of somatic cells from semen, diagram depicting Percoll layers prior to (A) and following (B) centrifugation.
- the present invention concerns the use of chromosomal replacement techniques in the context of producing cloned and transgenic animals, in order to correct chromosome abnormalities or alter autosomal genotypes, and provide for novel breeding pairs by replacing the sex chromosome in animals to be cloned.
- Replacement of a sex chromosome, or an X or Y chromosome will result in animals that are autosomally isogenic and sexually non-isogenic (AISN), with "autosomally isogenic” meaning that the paired sets of autosomes (non-sex chromosomes) in each animal are isogenic or identical.
- animals that are both "autosomally” and “allelically” isogenic whereby each particular pair of chromosomes is internally isogenic or identical within a single animal as well as between animals.
- the invention therefore encompasses methods of altering the sex of a cloned animal, or an animal to be cloned, or an embryo, blastocyst, fetus or cell comprising:
- a sex chromosome When a sex chromosome is removed according to the present invention, it may be either an X or a Y chromosome, and it may be replaced by the alternative sex chromosome from a non-isogenic allogeneic animal, or even a non-isogenic, xenogeneic animal.
- the Y chromosome In the case where the somatic cell of interest is from a male animal, the Y chromosome may be replaced by the X chromosome from another copy of the somatic cell to yield a cell with two X chromosomes.
- the somatic cell may need to be isolated from a sample of frozen cells.
- somatic cells preferably semen cells, may be frozen in preparation for the methodology of the invention.
- the alternative chromosome may be taken from a xenogeneic animal, preferably one that is closely related to the extinct animal.
- Application Serial No. pertains specifically to the cloning of endangered species, which material is hereby incorporated in its entirety.
- the chromosome to be replaced may be removed by any feasible technique.
- the unwanted chromosome may be removed by targeting by homologous recombination a gene or DNA sequence that results in loss of the chromosome upon mitosis or meiosis.
- chromosomal instability results when sequences are introduced which function as a centromere. Such sequences cause a dicentric chromosome to be created, which undergoes breakage potentially leading to loss of the chromosome during cell division. Loss of chromosomes that have been genetically modified with additional centromeric sequences can be detected by karyotype analysis.
- Cells which lose the targeted chromosome may be also be selected by including a negative selectable marker such as thymidine kinase whereby cells retaining the chromosome or pieces of the chromosome will not survive under selective conditions (i.e., gancyclovir in the case of thymidine kinase).
- a negative selectable marker such as thymidine kinase whereby cells retaining the chromosome or pieces of the chromosome will not survive under selective conditions (i.e., gancyclovir in the case of thymidine kinase).
- somatic cells as nuclear donors are that they may be expanded readily in culture prior to chromosome shuffling techniques.
- embryonic cells may also be used, as may the nuclei of somatic cells, which are advantageous in that they may be preserved in a preservative (such as alcohol) prior to nuclear transfer, i.e., stored for future use.
- Preferred somatic cells will be proliferating, i.e., in a proliferative state, but need not necessarily be expanded in culture.
- the somatic cells may be genetically altered in other ways prior to or subsequent to chromosome exchange.
- said cells may be modified with a chromosomal insertion or deletion, where a transgenic animal is desired that produces specific proteins in its bodily fluids or mammary glands, or where it is desirable to remove or mutate genes involved in xenotransplantation rejection.
- the alternative sex chromosome to be introduced may also be genetically altered from its native state.
- the methods of the present invention may be performed with a wide variety of animals, including mammals, fish, reptiles or birds.
- Preferred animals for agricultural and xenotransplantation uses to be made by the present invention are ungulates selected from the group consisting of bovine, porcine, sheep and goat.
- Preferred extinct or endangered animals to be reconstituted by the methods of the present invention include the gaur, bucardo, giant panda, cheetah, African bongo antelope, Sumarran tiger, Giant panda, Indian desert cat, moufion sheep and rare red deer.
- Preferred animals to be generated for laboratory use include mouse, hamster, guinea pig and primates. The methods may also be used to clone cats, dogs, horses or other companion animal, or breed champion lines of such mammals.
- the chromosomes to be inserted according to the claimed methods may be inserted via microcell-mediated chromsome transfer, or any other suitable technique known in the art, e.g., via injection.
- Methods for the preparation and fusion of microcells containing single chromosomes are well known. See, e.g., U.S. Patent Nos 5,240,840; 4,806,476; 5,298,429 (herein incorporated by reference in their entirety; see also Fournier, 1981 , Proc. Natl. Acad. Sci. USA 78: 6349-53; Lambert et al., 1991, Proc. Natl. Acad. Sci. USA 88: 5907-59; Yoshida et al., 1994, J.
- Chromosomes to be introduced into cloned cells or cells to be cloned will preferably include a selectable marker, such as aminoglycoside phosphotransferase, for example, so that cells receiving the chromosome via microcell fusion may be readily selected from those that do not.
- a selectable marker such as aminoglycoside phosphotransferase, for example.
- Siden and colleagues describe the construction of a panel of four microcell hybrids containing four separate insertions of the exogenous neomycin resistance gene into mouse chromosome 17. See Siden et al., 1989, Somat. Cell Mol. Genet. 15(3): 245-53.
- U.S. Patent No. 6,133,503 also describes methodology for producing microcells by treating a host donor cell with a mitotic spindle inhibitor such as colchicine, which results in the formation of micronuclei, then with cytochalasin B, which results in the extrusion of microcells which contain one or a few chromosomes.
- a mitotic spindle inhibitor such as colchicine
- cytochalasin B which results in the extrusion of microcells which contain one or a few chromosomes.
- the methods of U.S. Patent No. 5,635,376 are also helpful in the context of the present invention, in that this patent provides for female muntjac cell lines in which there is, for example, a ten-fold difference in chromosomal size between the diploid muntjac chromosomes and human chromosome 11.
- these female muntjac cell lines are useful for the amplification of desired chromosomes prior to use in cells to be cloned because desired chromosomes may be purified to apparent homogeneity from the resulting hybrids using conventional equipment given the large size difference between the chromosome of interest and the muntjac chromosomes.
- These patents are herein incorporated by reference in their entirety.
- the cloned animals, embryos, blastocysts, fetuses and cells produced by the methods described herein are also part of the invention, as are the sexual mates and breeding pairs produced and their offspring.
- the present invention includes methods of making an autosomally isogenic, allelically isogenic breeding pair of animals comprising:
- Such methods may be further supplemented by ensuring that the breeding pair of animals only produces animals of a single sex, by also including a step or steps whereby a nucleic acid construct is introduced into at least one sex chromosome of the germ line of said male animal, wherein said nucleic acid construct encodes a transgene which is expressed post-meiotically in developing spermatids, and wherein expression of said transgene alters the fertility of sperm resulting from said developing spermatids, such that said male produces progeny of a single sex.
- a nucleic acid construct is introduced into at least one sex chromosome of the germ line of said male animal, wherein said nucleic acid construct encodes a transgene which is expressed post-meiotically in developing spermatids, and wherein expression of said transgene alters the fertility of sperm resulting from said developing spermatids, such that said male produces progeny of a single sex.
- Inducing meiosis to produce a haploid cell from a somatic cell may be accomplished by any successful method.
- meiosis is accomplished by nuclear transfer of said somatic cell or the nucleus from said somatic cell (2n) into a metaphase II enucleated oocyte, and activating said nuclear transfer unit to extrude a polar body (n), thereby resulting in a haploid activated nuclear transfer unit.
- Activation may be accomplished by exposing said nuclear transfer unit to one or more treatments selected from the group consisting of hyaluronidase, ethanol, cytochalasin B, Ca 2+ ions, change in osmolarity, electrical pulse, bohemine, ionomycin and sperm factor.
- treatments selected from the group consisting of hyaluronidase, ethanol, cytochalasin B, Ca 2+ ions, change in osmolarity, electrical pulse, bohemine, ionomycin and sperm factor.
- Diploid cells containing isogenic alleles may be made by allowing the activated haploid oocyte to develop to at least the two cell stage, isolating and/or separating the cells, and fusing two allelically isogenic haploid cells from said developing activated oocyte into an enucleated metaphase II oocyte.
- the homozygous diploid may be made by isolating one haploid cell and allowing it to advance to the G2 phase of the cell cycle, at which point it is 2n or transiently diploid, and may be used as the donor nucleus for nuclear transfer.
- Some researchers have used cytochalasin B to induce diploidization of a female pronucleus following removal of the male pronucleus from a fertilized egg.
- allelically isogenic AISN breeding pairs include several embodiments. For instance, included are methods of making an autosomally isogenic, allelically isogenic breeding pair of animals comprising:
- Also included are methods of making an autosomally isogenic, allelically isogenic breeding pair of animals comprising:
- Also included are methods of making an autosomally isogenic, allelically isogenic breeding pair of animals comprising:
- a Y chromosome isolated from a male animal inserting a Y chromosome isolated from a male animal; (7) using nuclear transfer to create a first male animal that is autosomally isogenic, allelically isogenic and sexually non-isogenic to said haploid cell by fusing an isolated haploid cell or the nucleus therefrom selected from the expanded haploid cells of step (3) and the haploid cell or the nucleus therefrom from the haploid cell of step (7) with an enucleated metaphase II oocyte;
- Also included are methods of making an autosomally isogenic, allelically isogenic breeding pair of animals comprising:
- the female animal is made by fusing two isolated haploid cells or the nuclei therefrom containing X chromosomes selected from the expanded haploid cells of step
- step (7) (4) or the expanded haploid cells of step (7) with an enucleated metaphase II oocyte in order to create one animal that has two X chromosomes OR by fusing one isolated haploid cell at the G2 cell cycle stage containing an X chromosome with an enucleated metaphase II oocyte in order to create one animal that has two X chromosomes;
- the male animal is made by fusing one isolated haploid cell having an X chromosome with one isolated haploid cell having a Y chromosome with an enucleated metaphase II oocyte in order to create one animal that has an X and a Y chromosome; wherein sexual reproduction between said first animal and said second animal produces offspring that are autosomally isogenic and allelically isogenic to said first and second animal.
- the nuclear transfer units made by the methods of the present invention are also included.
- a female allelically isogenic diploid nuclear transfer unit may be made by a method comprising:
- step (3) one haploid cell from step (3) at the G2 cell cycle stage; with an enucleated metaphase II oocyte in order to create a female allelically isogenic diploid nuclear transfer unit.
- the method is performed such that the diploid nuclear transfer unit created at step (4) is activated such that there is no extrusion of a polar body.
- Activated diploid nuclear transfer units may further develop into an allelically isogenic cells, blastocysts, inner cell masses, ES cells, embryos, fetuses or animals.
- Methods of making male autosomally isogenic, allelically isogenic diploid nuclear transfer units are also included, and such methods may be performed by: (1) isolating a somatic cell from a preferred animal; (2) inducing meiosis of said somatic cell by nuclear transfer of said somatic cell or the nucleus from said somatic cell (2n) into a metaphase II enucleated oocyte and activating said nuclear transfer unit to extrude a polar body (n), thereby resulting in a haploid activated nuclear transfer unit; (3) allowing said haploid activated nuclear transfer unit to differentiate and expand to at least the two cell stage;
- the cell made in step (4) with an enucleated metaphase II oocyte in order to create a male autosomally isogenic, allelically isogenic diploid nuclear transfer unit.
- the allelically isogenic diploid nuclear transfer unit made by the methods of the invention are also encompassed. Because the methods described herein enable one to pass the advantages of the cloning technology to the agricultural and other industries while at the same time enable the control over the dissemination of genetically engineered molecules to remain with the inventor or the assignee, the methods described herein are particularly useful business models. Accordingly, the invention also includes business methods for producing uniform, isogenic animals, comprising:
- Female animals and/or said male animals may be genetically modified, bred or selected to provide an advantage in a desired market. For instance, in the agricultural market, female animals may be genetically modified, bred or selected to produce a high milk output, milk with specified lipid or protein profile, milk that contains a therapeutic protein, or milk with superior nutritional value. Alternatively, female and/or male animals may be genetically modified, bred or selected to produce meat, leather, wool or fiber having a desired characteristic.
- target markets include laboratories, where there is a need for isogenic animals including rats, monkeys, rabbits, mice, guinea pigs to remove the statistical noise from experimentation and trials for the development of therapeutic drugs.
- a target market would also include a xenotransplantation facility, where animals such as cows, pigs and primates are developed to provide compatible organs for human transplantation.
- female animals and/or male animals may be genetically modified with a specific human HLA type profile, or modified such that native proteins that cause graft rejection are deleted, modified or replaced with proteins that do not cause graft rejection in humans.
- male animal has been genetically modified such that it only produces offspring of a single sex, i.e., such that it only produces female offspring.
- Such a model is useful where only female uniform, isogenic animals are sold commercially. Frozen semen from a male isogenic animal may also be isolated and sold to purchasers of female uniform, isogenic animals such that artificial insemination may be used to create further uniform, isogenic animals.
- Male animals according to the invention may also be genetically modified such that they only produce male offspring, or such that they produce no offspring. This would be useful where only male uniform, isogenic animals are sold commercially. A single female isogenic animal could then sold or leased by purchasers of male uniform, isogenic animals such that purchasers may breed said female with a male in order to create further male uniform, isogenic animals.
- the uniform, isogenic animals produced in the business methods described herein are also included in the invention, as is semen, and kits containing frozen semen for artificial insemination.
- somatic cells can then be propagated, cryopreserved, or used as somatic cell donors for the production of nuclear transfer embryos and calves.
- An alternative approach would be to use a Fluorescence Cell Sorter machine, which can separate sperm from somatic cells based upon DNA content.
- fetuses may be extracted at 40 days, and fetal fibroblasts isolated and frozen. From these fetal fibroblasts, the final animals can be cloned.
- Cells can be isolated in a similar manner from other fluids such as milk, blood or urine where such samples have been saved.
- such cells can be cultured from frozen tissue such as skin biopsy, skeletal muscle, or whole frozen animals.
- Step 1 In a sterile 15 ml conical centrifuge tube, layer 2 ml 90% Percoll then carefully layer 2 ml of 45% Percoll on top of the 2 ml of 90% Percoll layer as shown in the diagram below. It is best to use either a 1000 ul pipette or a 9 ml pastuer pippete. It is very critical to have a very defined interface between the two layers. This will be observed clearly because the 45% Percoll is pinkish in hue and the 90% Percoll is clear. A very defined interface will be observed if layered correctly (see Figure 1A). Step 2: Thaw semen in 35°C water for 1 min. Record all information from semen straw, including bull name and registration numbers and collection date into your laboratory notebook.
- Step 3 Thoroughly dry the straw of semen with a KemWipe wet with ethanol and then snip end of semen straw with a clean scissor. Place the open end into a clean 15 ml conical tube. Then carefully snip off the plug end of the straw and deposit all semen into tube.
- Step 4 With a 500 ul pipette, carefully layer all of the semen onto the top of the Percoll layers.
- Step 5 Centrifuge at 700 x g (2000 rpm using a 6.37 inch tip radius) for 30 minutes.
- Step 6 After centrifugation, a sperm pellet will be observed at the bottom of the 90% Percoll layer as shown in .diagram below ( Figure IB).
- Step 7 Aspirate off the Percoll gradients leaving the sperm pellet in the tip of the tube. This is usually about only 200 ul of pellet (this will vary depending on the number of semen straws thawed).
- Step 8 With a clean pipette tip, move the pellet into either a 35 mm tissue culture treated plate or a 4 well Nunc plate with complete DMEM medium.
- Step 9 Remove the medium the following day and add fresh medium to the plates.
- Step 10 Carefully observe the plates for the presence of cells - this will depend on the semen, usually 7- 14 days after the initial plating.
- Step 11 follow standard Cell Culture Techniques once a cell line is observed.
- Modifiedsperm TL (lOx stock used to prepare 90% Percoll) A. Ingredients 1. 3.09 ml IM KCl.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23801400P | 2000-10-06 | 2000-10-06 | |
US238014P | 2000-10-06 | ||
PCT/US2001/031216 WO2002029002A2 (fr) | 2000-10-06 | 2001-10-05 | Procede pour creer des animaux clones par rearrangement chromosomique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1334356A2 true EP1334356A2 (fr) | 2003-08-13 |
EP1334356A4 EP1334356A4 (fr) | 2004-10-06 |
Family
ID=22896126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01981389A Withdrawn EP1334356A4 (fr) | 2000-10-06 | 2001-10-05 | Procede pour creer des animaux clones par rearrangement chromosomique |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1334356A4 (fr) |
AU (1) | AU2002213033A1 (fr) |
CA (1) | CA2425100A1 (fr) |
WO (1) | WO2002029002A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10248361A1 (de) * | 2002-06-30 | 2004-01-22 | Beisswanger, Roland, Dr. | Unterdrückung eines Geschlechtes durch die Veränderung von Geschlechtschromosomen |
CN114457360B (zh) * | 2022-02-11 | 2023-08-25 | 中国华能集团清洁能源技术研究院有限公司 | 一种无隔膜微电解槽放大设备及加工方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240840A (en) * | 1991-04-05 | 1993-08-31 | Regents Of The University Of Michigan | Dna superfragment cloning |
WO1999037143A2 (fr) * | 1998-01-21 | 1999-07-29 | University Of Hawaii | Developpement a terme d'animaux a partir d'ovocytes enuclees reconstitues avec des noyaux de cellules somatiques adultes |
WO2000042174A1 (fr) * | 1999-01-13 | 2000-07-20 | Ppl Therapeutics (Scotland) Limited | Procede de double transfert de noyau et resultats de ce transfert |
WO2002077175A2 (fr) * | 2001-03-23 | 2002-10-03 | Advanced Cell Technology, Inc. | Procede de generation d'animaux clones par rearrangement de chromosomes |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270201A (en) * | 1988-03-24 | 1993-12-14 | The General Hospital Corporation | Artificial chromosome vector |
US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
-
2001
- 2001-10-05 WO PCT/US2001/031216 patent/WO2002029002A2/fr active Application Filing
- 2001-10-05 AU AU2002213033A patent/AU2002213033A1/en not_active Abandoned
- 2001-10-05 CA CA002425100A patent/CA2425100A1/fr not_active Abandoned
- 2001-10-05 EP EP01981389A patent/EP1334356A4/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240840A (en) * | 1991-04-05 | 1993-08-31 | Regents Of The University Of Michigan | Dna superfragment cloning |
WO1999037143A2 (fr) * | 1998-01-21 | 1999-07-29 | University Of Hawaii | Developpement a terme d'animaux a partir d'ovocytes enuclees reconstitues avec des noyaux de cellules somatiques adultes |
WO2000042174A1 (fr) * | 1999-01-13 | 2000-07-20 | Ppl Therapeutics (Scotland) Limited | Procede de double transfert de noyau et resultats de ce transfert |
WO2002077175A2 (fr) * | 2001-03-23 | 2002-10-03 | Advanced Cell Technology, Inc. | Procede de generation d'animaux clones par rearrangement de chromosomes |
Non-Patent Citations (5)
Title |
---|
"CAN CLONING SAVE ENDANGERED SPECIES?" CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 11, no. 7, 2000, pages R245-R246, XP002909800 ISSN: 0960-9822 * |
BOURHIS LE D ET AL: "NUCLEAR TRANSFER FROM SEXED PARENT EMBRYOS IN CATTLE: EFFICIENCY AND BIRTH OF OFFSPRING" JOURNAL OF REPRODUCTION AND FERTILITY, JOURNALS OF REPRODUCTION AND FERTILITY LTD, GB, vol. 113, no. 2, July 1998 (1998-07), pages 343-348, XP000922632 ISSN: 0022-4251 * |
See also references of WO0229002A2 * |
WHITE K L ET AL: "ESTABLISHMENT OF PREGNANCY AFTER THE TRANSFER OF NUCLEAR TRANSFER EMBRYOS PRODUCED FROM THE FUSION OF ARGALI (OVIS AMMON) NUCLEI INTO DOMESTIC SHEEP (OVIS ARIES) ENUCLEATED OOCYTES" CLONING, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 1, no. 1, 1999, pages 47-54, XP002909799 ISSN: 0737-1454 * |
WOLF E ET AL: "Nuclear transfer in mammals: Recent developments and future perspectives" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 65, no. 2-3, 27 October 1998 (1998-10-27), pages 99-110, XP004144916 ISSN: 0168-1656 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002029002A2 (fr) | 2002-04-11 |
AU2002213033A1 (en) | 2002-04-15 |
EP1334356A4 (fr) | 2004-10-06 |
WO2002029002A3 (fr) | 2002-09-19 |
CA2425100A1 (fr) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Krimpenfort et al. | Generation of transgenic dairy cattle using ‘in vitro’embryo production | |
Li et al. | Cloned ferrets produced by somatic cell nuclear transfer | |
US5523226A (en) | Transgenic swine compositions and methods | |
US20020174449A1 (en) | Method for generating cloned animals using chromosome shuffling | |
Heyman | Nuclear transfer: a new tool for reproductive biotechnology in cattle | |
JP4102450B2 (ja) | 胎仔線維芽細胞による効率的な核移入 | |
WO1998027214A1 (fr) | Production d'ongules chimeriques et transgeniques a l'aide de cellules souches embryonnaires | |
US6700037B2 (en) | Method of cloning porcine animals | |
JP2003512848A (ja) | 遺伝的診断、修飾および増殖のための一倍体ゲノムの使用 | |
Skrzyszowska et al. | Generation of transgenic rabbits by the novel technique of chimeric somatic cell cloning | |
US20040040050A1 (en) | Production of agricultural animals from embryonic stem (es) cells | |
US7071372B2 (en) | Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells | |
US20040139489A1 (en) | Method for generating cloned animals using chromosome shuffling | |
Basrur et al. | Genetics then and now: breeding the best and biotechnology | |
WO2002029002A2 (fr) | Procede pour creer des animaux clones par rearrangement chromosomique | |
US20040031069A1 (en) | Cloning endangered and extinct species | |
JP2001103867A (ja) | 再構築受精卵の作製方法及びそれを用いたトランスジェニック胚の作製方法 | |
US7351876B2 (en) | Efficient nuclear transfer with primordial gametes | |
US20060021070A1 (en) | Production of chimeric bovine or porcine animals using cultured inner cell mass | |
JP4903392B2 (ja) | 遺伝子ホモ改変哺乳動物細胞、遺伝子ホモ改変非ヒト哺乳動物、及びそれらの樹立、作出方法。 | |
US20230220331A1 (en) | Temporary treatment medium, treatment kit, embryogenesis arrest inhibitor, embryogenesis arrest inhibitory method, developmental engineering product preparation method, transplantation method, therapeutic method, and developmental engineering product | |
AU747070B2 (en) | Efficient nuclear transfer using primordial germ cells | |
US20040077077A1 (en) | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same | |
Gou et al. | Transgenic twin lambs cloned by granulosa cells | |
US20060174358A1 (en) | Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030506 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 01K 67/027 A |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WEST, MICHAEL, D. Inventor name: DAMIANI, PHILIP Inventor name: CIBELLI, JOSE Inventor name: LANZA, ROBERT |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040824 |
|
17Q | First examination report despatched |
Effective date: 20070801 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071212 |